Michael Sanley, MD
Pulmonary Disease · Omaha, NENPI 1437388741
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (59.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 67.3% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $11,985 and has fallen 91.8% since, to $980 in 2025.
Across 302 payments — averaging $54.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- United Therapeutics Corporation$894
- AstraZeneca$800
- Boehringer Ingelheim$577
- Actelion Pharmaceuticals US, Inc.$418
- GSK$307
- plus $2K from 33 others
What the payments were for
- Travel & lodging$1,0136%
- Food & beverage$5,70134%
- Education$9,81359%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $11,121 |
| United Therapeutics Corporation | 45 | $894 |
| AstraZeneca | 25 | $800 |
| Boehringer Ingelheim | 32 | $577 |
| Actelion Pharmaceuticals US, Inc. | 20 | $418 |
| GSK | 28 | $307 |
| Insmed, Inc. | 12 | $248 |
| Genentech USA, Inc. | 10 | $190 |
| Sanofi | 10 | $172 |
| Electromed, Inc. | 17 | $163 |
| Grifols USA, LLC | 8 | $140 |
| Harmony Biosciences LLC | 7 | $135 |
| Bayer | 6 | $132 |
| Regeneron Healthcare Solutions, Inc. | 8 | $126 |
| Amgen | 7 | $116 |
| Portola Pharmaceuticals, LLC | 1 | $108 |
| Verona Pharma, Inc. | 5 | $96 |
| Philips North America LLC | 5 | $91 |
| Jazz Pharmaceuticals Inc. | 3 | $62 |
| Baxter Healthcare | 3 | $60 |
| Johnson & Johnson | 4 | $56 |
| Medtronic | 2 | $55 |
| Gilead | 4 | $53 |
| Sunovion Pharmaceuticals Inc. | 7 | $49 |
| Pulmonx Corporation | 1 | $42 |
| Melinta Therapeutics, LLC | 3 | $41 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $29 |
| Shire North American Group Inc | 2 | $28 |
| Applied Medical Technology Inc | 1 | $28 |
| Resmed Corp | 2 | $28 |
| Advanced Respiratory, Inc | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Liquidia Technologies, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Merck | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$10,704
- FASENRA$408
- AIRSUPRA$285
- BREZTRI$285
- DA VINCI SP$172
- ANDEXXA$108
How this compares
$16,526 in reported general payments places this provider in the 85th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 25 | $572,697 |
| OfevNintedanib Esylate | 12 | $155,418 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 147 | $109,387 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $48,812 |
| Dupixent SyringeDupilumab | 11 | $41,887 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $40,227 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $33,380 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $18,695 |
| Spiriva RespimatTiotropium Bromide | 15 | $14,732 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $11,869 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $10,399 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 56 | $5,635 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,961 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $4,677 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 151 | $3,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $307 | $194,863333 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $577 | $188,84461 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $800 | $59,211100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
- Lee MorrowOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.